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Ovarian seromucinous tumors:
clinicopathological features of 10 cases
with a detailed review of the literature
Romana Idrees1, Nasir Ud Din1, Sabeehudin Siddique1, Saira Fatima1, Jamshid Abdul-Ghafar2* and
Zubair Ahmad1
Abstract
Background: The 2014 WHO Classification of ovarian neoplasms introduced a new entity of seromucinous tumors
associated with endometriosis. These tumors encompassed a spectrum from benign to malignant and included
seromucinous cystadenoma/ cystadenofibroma, seromucinous borderline tumor/atypical proliferative seromucinous
tumor and seromucinous carcinoma. However, the 2020 WHO Classification of Female Genital Tumours removed
seromucinous carcinomas as a distinct entity and recategorized them as Endometrioid carcinomas with mucinous
differentiation. Here we describe clinico-morphologic features of seromucinous tumors recategorizing cases
originally diagnosed as seromucinous carcinoma in light of 2020 WHO classification and present detailed review of
literature.
Methods: Slides of seromucinous tumors were reviewed. Special emphasis was given to evaluation of stromal
invasion. Follow-up was obtained.
Results: Ten cases were diagnosed. Mean age was 40 years. Four cases were bilateral. Mean size was 19 cm. Grossly;
luminal papillary projections were seen in 6 cases. Tumors demonstrated a papillary architecture with papillae lined
by stratified seromucinous epithelium showing nuclear atypia. Stromal invasion was seen in 4 cases. Six cases were
reported as borderline seromucinous tumors and 4 cases originally diagnosed as seromucinous carcinoma were
recategorized as endometrioid carcinoma with mucinous differentiation on review. Endometriosis was seen in 4
cases. CK7, PAX8 and ER were positive in 7/7 cases. Two cases showed extra-ovarian involvement. Follow up was
available in 7 cases. Six patients were alive and well at follow up ranging from 8 to 46 months. Six patients received
chemotherapy postoperatively. One patient with carcinoma died of disease 18 months postoperatively.
Conclusion: In our series, 4 cases were originally diagnosed as seromucinous carcinomas. However, these were
recategorized in light of the 2020 WHO Classification of Female Genital tumors as endometrioid carcinomas with
mucinous differentiation. Six cases were diagnosed as seromucinous borderline tumors. Thus, majority of cases
were borderline in agreement with published literature.
Keywords: Borderline tumor, Concomitant ovarian tumor, Endometriosis, Stromal invasion, Seromucinous
carcinoma, Endometrioid carcinoma with mucinous differentiation
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Background
The 4th edition World Health Organization (WHO)
classification of Tumors of Female Reproductive Organs
published in 2014 made a number of modifications in
the classification of ovarian tumors especially epithelial
tumors, modified the grading system for serous carcin-
omas. It also identified a new morphological group of
seromucinous tumors which are believed to be derived
from or associated with endometriosis in a number of
cases. These tumors in the 2014 classification encom-
passed a spectrum from benign to malignant and in-
cluded seromucinous cystadenoma/cystadenofibroma,
seromucinous borderline tumor/atypical proliferative
seromucinous tumor and seromucinous carcinoma.
These tumors are morphologically composed of serous
and mucinous (endocervical type) epithelium. Foci com-
posed of transitional, squamous, clear cell or endome-
trioid epithelium are sometimes seen. These tumors
were first described in 2002. However, the 5th edition of
WHO Classification of Female Genital Tumors pub-
lished in 2020 has removed seromucinous carcinoma as
a distinct entity and now considers it as a subtype of
endometrioid carcinoma. In 2012, the International Fed-
eration of Gynecology and Obstetrics (FIGO) Oncology
Committee revised the FIGO Classification for staging of
ovarian, tubal and primary peritoneal cancers and the
new FIGO Staging Classification was published and be-
came effective in early 2014 [1–6]. We had diagnosed 10
cases of ovarian seromucinous tumors in our practice
since their inclusion in the 2014 WHO classification as a
distinct entity. Herein, we aim to discuss the clinicopath-
ological features of these 10 cases and the recategoriza-
tion of the cases originally diagnosed as seromucinous
carcinoma in the light of the new 2020 WHO Classifica-
tion of Female Genital Tumours. We believe that this is
the first series of seromucinous ovarian tumors from
South Asia. We also present a detailed review of the
published literature on these rare tumors.
Methods
The Surgical Pathology files of the Section of Histopath-
ology were searched for all cases of ovarian tumors diag-
nosed as seromucinous tumors. All cases diagnosed as
seromucinous cystadenoma, seromucinous borderline
tumor or seromucinous carcinoma between January 1,
2015 and December 31, 2019 were included in the study.
Clinical features of all diagnosed cases were recorded.
Hematoxylin and Eosin (H&E) slides of all cases were re-
trieved and blindly reviewed by the two principal authors
(RI and ZA). Clinical and pathological features of all
cases were described. All cases were carefully evaluated
for stromal invasion. Special stain Periodic acid–Schiff
(PAS) ± Alcian Blue (AB) was used to highlight the intra-
cellular acid mucin. Immunohistochemical (IHC) stains
for Cytokeratin (CK) 7 (monoclonal mouse anti human,
ready to use, Glostrup, Dako, Denmark), and PAX8
(anti-PAX8, mouse monoclonal primary antibody, Cell
Marque, Rocklin, CA, USA) were used to demonstrate
expression in epithelial cells. CK20 (monoclonal mouse
anti human, ready to use, Glostrup, Dako, Denmark), Es-
trogen Receptor (ER) (monoclonal rabbit anti human,
clone EP1, ready to use, Glostrup, Dako, Denmark), Pro-
gesterone Receptor (monoclonal anti human, clone
PgR636, ready to use, Glostrup, Dako, Denmark), Wilms
Tumor 1 (WT1) (monoclonal mouse, anti- human, ready
to use, Glostrup, Dako, Denmark), and CDX2 (monoclo-
nal mouse anti-human, ready to use, Glostrup, Dako,
Denmark) were performed in selected cases. Clinical fol-
low up was obtained from the patients or family
members.
Results
A total of 10 seromucinous ovarian tumors were re-
ported during the study period. Details of clinicopatho-
logical features are shown in Table 1. Ages of the
patients ranged from 25 to 57 years with mean and me-
dian age of 40 and 41 years, respectively. The tumors
were bilateral in 4 cases (40%), left ovary alone was in-
volved in 2 cases (20%) while right ovary alone was in-
volved in 3 cases (30%). In 1 case, laterality was not
known. Symptoms included abdominal pain, swelling
and distension, bleeding per vagina etc. and were present
in 9 cases for several months before the patients sought
medical attention. One patient, however, had a short
two-day history of severe abdominal pain following cyst
rupture and secondary peritonitis. Magnetic Resonance
Imaging (MRI) and ultrasound revealed large cystic
masses in the ovaries. The cysts were multi-septate and
uni or multilocular.
Hysterectomy with bilateral salpingo-oophorectomy
was performed in 6 cases (60%), while ovarian cystec-
tomy was performed in 4 cases (40%). On gross examin-
ation, sizes of cysts ranged from 7 cm to 35 cm with
mean size of 19 cm. Cysts were bi or multilocular in 7
cases (70%) and unilocular in 3 cases (30%).
External surfaces of cysts were smooth in 9 cases
(90%) (Fig. 1a). On opening, the cysts were filled with
light brown to hemorrhagic myxoidy material (Fig. 1b).
In 1 case, the external surface showed cauliflower like
projections. In 6 cases (60%), inner surfaces of cysts
demonstrated multiple papillary excrescences or
projections.
In all 10 cases, multiple sections were submitted for
histologic examination. On histologic examination, a
branching papillary architecture with fibrovascular
cores was seen in all 10 cases. The epithelium lining
the papillae was stratified and composed of endocervi-
cal type mucinous epithelium in some areas and
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serous epithelium in others (Fig. 2a-d). Epithelium
was predominantly serous in 7 (70%) cases and pre-
dominantly mucinous in 3 (30%) cases. Epithelial cells
in all 10 cases demonstrated nuclear pleomorphism
and hyperchromasia, irregular nuclear contours,
coarse chromatin and occasional prominent nucleoli
(Fig. 2a-d). Diagnosis of borderline seromucinous
tumor was given in 6 cases. A fibromatous stroma
was seen in all borderline tumors (Fig. 3a-b). Scat-
tered mitotic figures were seen in all 10 cases. Tumor
necrosis was seen in 3 (30%) cases. Clear cells were
seen in 3 (30%) cases (Fig. 4a, b) while squamous epi-
thelium was focally seen in 1 case. Stromal invasion
was seen in 4 out of 10 cases resulting in 4 cases be-
ing diagnosed as seromucinous carcinoma (Fig. 4c, d).
However, on reviewing the slides in view of the latest
WHO Classification of Female Genital Tract Tumors,
all 4 tumors were recategorized as endometrioid car-
cinomas with mucinous differentiation (Fig. 5a, B
Concomitant endometrioid adenocarcinoma (in
contralateral ovary) and concomitant granulosa cell
tumor in the same ovary (Fig. 6a-d) were seen in 1
case each. In 4 cases, tubal or ovarian endometriosis
was noted. The tumors were confined to the ovary in
8 cases. In 1 case with bilateral borderline seromuci-
nous tumor, both fallopian tubes and myometrium
were invaded by the tumor while the pelvic lymph
nodes, appendix and omentum demonstrated meta-
static tumor deposits. Cytoplasmic acid mucin was
highlighted in the mucinous cells on special stain
PAS ± AB (Fig. 5a inset). Immunohistochemistry was
performed in 7 out of 10 cases. The tumor cells in all
7 cases expressed IHC stains for PAX8, ER and CK7
(Fig. 7a, b, c) and PR and were negative for CK20,
Table 1 Clinicopathological data of cases in our series (n = 10)
S.No Age (years) Laterality Size (cm) Histological diagnosis
1 41 Left 7x7x3 Endometriod carcinoma with mucinous differentiation
2 25 Not Known 35 × 34 Borderline seromucinous tumor
3 32 Right 11.5 × 10.5 Borderline seromucinous tumor
4 50 Bilateral Right 25 × 29
Left 10 × 6
Borderline Seromucinous tumor
5 54 Not Known Not Known Seromucinous carcinoma & Adult granulosa cell tumor
6 34 Not Known 23 × 13.5 Borderline seromucinous tumor
7 36 Left 6x4x4 Borderline seromucinous tumor
8 57 Bilateral Left 10 × 7
Right 10 × 9.5
Borderline seromucinous tumor
9 50 Right 18 × 12 Seromucinous carcinoma
10 53 Right 12 × 5 Seromucinous carcinoma
Fig. 1 a Picture of an ovarian seromucinous borderline tumour. The capsule is intact with smooth outer surface. Note the attached fallopian tube
(→). b On opening the cyst shows multiple locules (→) that were filled with thick myxoidy material
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CDX2 and WT1. In 1 additional case, a right ovarian
endometrioid carcinoma with mucinous differentiation,
right fallopian tube showed direct tumor invasion while
the omentum showed metastatic tumor. Pelvic lymph
nodes were received in 3 cases. They were negative in 2
cases and 1 case (described above) showed involvement of
lymph nodes by metastatic tumor.
Follow-up was available in 7 cases. One patient with
endometrioid carcinoma with mucinous differentiation
who had involvement of right tube and omentum (de-
scribed above) died 18-months postsurgical resection.
She had received chemotherapy post resection. Six pa-
tients were alive and well at follow up periods ranging
from 8 to 46 months. Five of these 6 patients received
chemotherapy postsurgical resection (Table 2).
Discussion
In a 2016 paper, Kurman and Shih presented a revised
and expanded model of ovarian carcinogenesis dividing
type I ovarian tumors into 3 groups: (i) endometriosis
related tumors (clear cell, endometrioid and seromuci-
nous carcinomas) (ii) low grade serous carcinomas and
(iii) mucinous carcinomas and malignant Brenner tu-
mors [7]. Women with endometriosis have been shown
to have a two to three-fold increased risk of developing
Fig. 2 a-d. Seromucinous borderline tumor. Papillae with fibrovascular cores lined by stratified epithelium. Both serous (↓) and mucinous (→)
epithelium in different areas of the tumor (H&E × 20)
Fig. 3 a Most of the seromucinous borderline tumors had fibromatous stroma. b both endocervical type mucinous columnar epithelium (→) and
ciliated serous epithelium (↓) are seen in the same field (H&E × 20)
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ovarian cancers especially endometrioid and clear cell
carcinomas [8, 9]. Recent molecular research has greatly
improved our knowledge of various subtypes of ovarian
cancers and has an important impact on prognosis and
therapy [9].
Seromucinous tumors were first described by Shappell
et al. in 2002. They described the clinicopathologic fea-
tures of 54 ovarian tumors with papillary architecture,
predominantly ciliated serous type epithelium as well as
endocervical mucinous epithelium. Of their 54 cases,
Fig. 4 a Tumor cells with clear cytoplasm were seen in 2 cases. b An area with clear cells, papillary structures and psammomatous calcifications.
C&D). Seromucinous carcinoma with stromal invasion
Fig. 5 Seromucinous carcinoma recategorized as endometrioid adenocarcinoma with mucinous differentiation. a Variably dilated glands lined by
columnar epithelium with mucinous cytoplasm. (Inset) PAS special stain depicting cytoplasmic mucin. b In other areas, high grade tumor was
noted with cribriform pattern and pleomorphic columnar lining cells
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they classified 34 (63%) as atypical proliferative (border-
line), 5(9%) as intraepithelial carcinoma, 8 (15%) as
microinvasive carcinoma, and 7 (13%) as carcinoma [3].
Although seromucinous tumors were included in the
2014 WHO Classification as a distinct tumor type, a
paper by Kurman and Shih published in 2016 again cast
doubt on the terminology of seromucinous tumors and
questioned whether these tumors truly constituted a dis-
tinct type of ovarian tumor. They stressed that
morphologic, immunohistochemical and molecular gen-
etic findings show that seromucinous tumors do not
show serous-type differentiation and emphasized that
the evidence in fact linked these tumors to clear cell and
endometrioid tumors. According to the authors, sero-
mucinous tumors are mullerian in origin, characterized
by an admixture of various cell types including
endocervical-type mucinous, endometrioid and squa-
mous type epithelium and have a close relationship with
Fig. 6 a-c Seromucinous borderline tumor with co-existent adult granulosa cell tumor. d The granulosa tumor cells were positive for Inhibin stain
Fig. 7 Positive expression of ER (a), PAX 8 (b) and CK7 (c) by tumor cells
Idrees et al. Journal of Ovarian Research           (2021) 14:47 Page 6 of 10
endometriosis similar to clear cell and endometrioid tu-
mors. Thus, they regarded seromucinous carcinoma as a
variant of endometrioid carcinoma. They recommended
that these tumors be subcategorized as “mixed mullerian
cystadenomas, “mixed mullerian atypical proliferative
(borderline) tumors”, and “mixed mullerian carcinomas”
[10]. Another recent study by Rambau et al. also con-
cluded that the morphologic diagnosis of seromucinous
carcinomas is not very reliable and stressed that these
tumors do not express a distinct immunophenotype or
genotype. They examined 32 cases which had been diag-
nosed as seromucinous carcinomas and reported sub-
optimal interobserver reproducibility for diagnosis of
these tumors. They recategorized all 32 cases as endo-
metrioid (23), low grade serous (9) and mucinous (1)
carcinomas. They suggested that the category of seromu-
cinous carcinomas be discontinued as with ancillary mo-
lecular tests these tumors can be assigned to one of the
major tumor categories [11]. In other words, seromuci-
nous carcinoma and endometrioid carcinoma with mu-
cinous differentiation, commonly endocervical like, may
show similar and overlapping histological features and
their distinction may be arbitrary. In a recent review of
ovarian seromucinous tumors, Nagamine and Mikami
also recommended that category of seromucinous car-
cinoma be removed from the classification. According to
them, seromucinous carcinomas represent endometrioid
carcinomas with mucinous differentiation and should be
regarded as a variant of endometrioid carcinoma. Ac-
cording to the authors, seromucinous tumors are bor-
derline in most cases. Nagamine and Mikami as well as
Shappell et al. in an earlier study regard high grade nu-
clear atypia in seromucinous tumors without destructive
stromal invasion as “intraepithelial carcinoma” and term
frank stromal invasion of < 5 mm in greatest dimension
in borderline tumors as “seromucinous borderline tu-
mors with microinvasion” [3, 12]. The 2020 5th Edition
of WHO Classification of Female Genital Tumors has
removed ‘Seromucinous Carcinoma’ as a distinct entity
after first including it in the 2014 4th Edition. It now
only recognizes the benign and borderline seromucinous
tumors as distinct entities and maintains that
‘Seromucinous carcinoma’ has been removed because it
was a poorly reproducible diagnosis and there is signifi-
cant morphological overlap with endometrioid carcin-
oma. It asserts that immunohistochemical and molecular
studies also suggest that most cases diagnosed as ‘sero-
mucinous carcinoma’ actually represents unusual mor-
phological patterns of endometrioid carcinoma. It now
considers seromucinous carcinoma as a subtype of endo-
metrioid carcinoma with mucinous differentiation [5, 6].
There is no doubt regarding the close relationship of
seromucinous ovarian tumors with ovarian endometri-
osis and with other ovarian tumors such as endome-
trioid and clear cell tumors which also demonstrate a
similar close relationship to endometriosis. This is also
evident from the fact that endometriosis related ovarian
tumors including seromucinous, clear cell and endome-
trioid tumors show ARID1A mutations with loss of
ARID1A expression in a high proportion of cases. Inter-
estingly, a large recent study of endometrioid endomet-
rial carcinoma found a seromucinous component in over
9% of cases and furthermore found that the presence of
seromucinous component was associated with a better
prognosis in these tumors with a longer progression free
survival [13]. Each of these tumors, however, shows add-
itional characteristic molecular alterations which may be
increasingly relevant clinically for developing targeted
therapies [8–10]. Since seromucinous tumors are very
rare, epidemiological data is scanty. However, these tu-
mors have mostly been reported in adults especially in
the late reproductive age. Mean and median age in our
series of cases were 42 and 41 years respectively. In mul-
tiple reported series, mean age of seromucinous carcin-
omas was 45, 47, and 48 years respectively which are
similar to our findings [3, 14, 15]. However, in one re-
cent series, mean age for borderline seromucinous tu-
mors and seromucinous carcinomas was much older-
63.2 and 68.3 years respectively [16]. Whereas seromuci-
nous cystadenomas/cystadenofibromas are completely
benign, seromucinous borderline tumors also appear to
have a good prognosis even in the presence of peritoneal
implants. On the other hand, tumors originally diag-
nosed as advanced stage seromucinous carcinomas
Table 2 Details of Follow up (n = 7)
S.No Year resected Chemotherapy Length of follow up (months) Alive Dead
1 2016 Yes 46 Yes –
2 2016 No 42 Yes –
3 2018 Yes 25 Yes –
4 2018 Yes 18 No Died Nov, 2019
5 2019 Yes 12 Yes –
6 2019 Yes 9 Yes –
7 2019 Yes 8 Yes –
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appeared to have a bad prognosis although very little
data was available [17].
Signs and symptoms in our series were nonspecific
and included lower abdominal pain and swelling. Similar
nonspecific clinical presentation is reported in literature.
In Tang et al’s series of 7 cases, most patients presented
with abdominal distension [15]. Radiologically, 7 cases in
our series showed multilocular cysts (with focal solid
component in 2 cases) while 3 cases showed unilocular
cysts. MRI reveals unilocular or multilocular cysts in be-
nign cases while borderline and malignant tumors ap-
pear as complex cystic-solid masses [18].
A recent study which looked at the MRI findings of
seromucinous tumors found evidence of endometriosis
in more than half the cases and concluded that it was
difficult to differentiate tumors diagnosed as seromuci-
nous carcinomas from other endometriosis related car-
cinomas by imaging studies [14]. However, some other
recent imaging studies have found certain imaging fea-
tures on MRI which can help in distinguishing seromu-
cinous tumors from other malignant ovarian tumors
including endometriosis related tumors [19, 20].
In our series, tumor laterality was known in 9 out of
10 cases, 5 cases were unilateral and 4 were bilateral. In
multiple published series, the majority of cases were uni-
lateral (16 out of 19 in one series, 5 out of 7 in another).
In Shappel’s series of 54 cases, 70% were unilateral [3,
14, 15].
Our cases ranged in size from 7 to 35 cm with mean
size of 19 cm in the largest dimension. In various pub-
lished series, tumor sizes ranged from 1.8 to 18 cm with
mean size of 9.3 cm, 10.5 cm and 12 cm [3, 14, 15, 17].
According to Nagamine and Mikami, mean size of bor-
derline seromucinous tumors is 8–10 cm [12].
In our series, external surfaces of the cysts were
smooth in 9 out of 10 cases while 6 cases demonstrated
papillary projections on the inner surfaces. Papillary pro-
jections on inner surfaces of cysts in cases reported ori-
ginally as ovarian seromucinous carcinomas have been
reported in multiple series [3, 12, 16].
On histological examination, all 10 cases in our study
revealed architectural atypia in the form of branching
papillae and a confluent glandular pattern as well as
cytological atypia in the form of atypical seromucinous
epithelium. Endometriosis was seen in 4 cases. Endomet-
riosis has been noted in 30–70% seromucinous tumors.
Mucinous cells are endocervical type. Goblet cells and
Paneth cells which are indicators of gastrointestinal dif-
ferentiation are usually absent and were not seen in any
of our cases. Scattered squamous and clear cells were
seen in 1 and 2 cases respectively. Of the 10 cases, 4
demonstrated stromal invasion consistent with a diagno-
sis of seromucinous carcinoma. The histologic features
in 3 of these 4 cases corresponded closely with the
histologic features of seromucinous carcinomas de-
scribed in published studies [3, 14, 15, 17]. However,
in view of exclusion of seromucinous carcinoma as a
distinct entity from the 2020, the 5th Edition of
WHO Classification of Female Genital Tract Tumors
and its recategorization as Endometrioid carcinoma
with mucinous differentiation [5], we recategorized all
4 cases as endometrioid carcinoma with mucinous
differentiation on retrospective slide review. In 6
cases, the histological appearance corresponded to the
histological features described for seromucinous bor-
derline tumors [3, 14, 15, 17].
Borderline seromucinous tumors and endometrioid
carcinoma with mucinous differentiation are usually
positive for IHC stains CK7, ER, PR and CA125 as well
as PAX8 and are usually negative for CK20, CDX2 and
WT1. The positivity for ER and negativity for WT1 is
also suggestive of a close relationship with endometrioid
and clear cell ovarian tumors [13, 14, 21]. On IHC
stains, all our cases demonstrated positivity for CK7,
PAX 8, ER and PR and were negative for CK20, CDX2
and WT1. WT1 was negative in areas of serous epithe-
lium also. This is true for seromucinous tumors. The
negativity for CK20, CDX2, and WT1 and positivity for
ER and PR is useful in routine practice in differentiating
borderline seromucinous tumors from borderline serous
and mucinous tumors. Serous borderline tumors are al-
most always positive for WT1 while mucinous border-
line tumors are variably positive for CK20 and CDX2
and negative for ER and PR [12]. Thus, our findings
were similar to published international data [13, 14, 21].
In 1 of our cases, concomitant endometrioid adenocar-
cinoma was seen in the other ovary. In another case,
concomitant granulosa cell tumor was present in the
same ovary. A number of case reports have been pub-
lished documenting the coexistence of seromucinous
borderline tumor and cases originally diagnosed as sero-
mucinous carcinoma of the ovary with other malignant
ovarian tumors [22–24].
About 90% borderline seromucinous tumors have
FIGO Stage I disease. The remaining show extraovarian
disease in the form of peritoneal implants and/or lymph
node involvement. Even such patients usually have an
excellent prognosis [12, 16]. It must be remembered that
the peritoneal implants may be misinterpreted as dis-
seminated adenocarcinoma on frozen sections [12].
We have used the term ‘extraovarian disease’ for the 2
cases which showed direct invasion of one or both fallo-
pian tubes and/or myometrium and metastatic involve-
ment of pelvic lymph nodes, appendix and/or omentum.
Although seromucinous carcinomas have now been
recategorized as endometrioid carcinomas with mucin-
ous differentiation, the cases originally reported as such
demonstrated gross and microscopic features similar to
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seromucinous borderline tumors including papillary pro-
jections, high grade cytologic atypia and architectural
complexity. Mitotic index is usually < 5 mitoses/10HPFs.
No stage IV seromucinous carcinomas were ever re-
ported, and one 2017 study found that the so called ser-
omucinous carcinomas comprised 4% of all ovarian
carcinomas and had a 55% five-year survival rate [17].
Follow up was available in 7 cases. Length of follow up
in our study ranged from 8 to 46months. Chemotherapy
was given in 6 out of 7 cases. One out of the 7 patients
died. In 6 of our 10 cases, hysterectomy with bilateral
salpingo-oophorectomy and in 4 cases cystectomy alone
was performed. Nagamine and Mikami believe that pa-
tients who have been treated with cystectomy alone, es-
pecially those of reproductive age, can be managed
conservatively without any further treatment if no re-
sidual disease is seen on imaging studies. However, they
recommend that such patients should be clearly in-
formed about the risk of recurrence or involvement of
contralateral ovary and should be strongly counselled on
the need for long term follow up [12].
Conclusions
In conclusion, out of 10 seromucinous ovarian tumors in
our series, 6 were diagnosed as seromucinous borderline tu-
mors and 4 cases originally diagnosed as seromucinous car-
cinomas were recategorized on slide review as endometrioid
carcinomas with mucinous differentiation. Seromucinous
ovarian tumors demonstrate relatively special clinicopatho-
logical features but often have overlapping morphologic and
immunophenotypical features with other ovarian carcinomas
including endometrioid carcinomas and low-grade serous
carcinomas. However, a panel IHC approach is useful in dif-
ferentiating them from their histological mimics. Even after
their inclusion in the 2014 WHO classification of ovarian tu-
mors as a distinct entity, many authors still believed that it is
necessary to investigate their pathogenesis and molecular fea-
tures even more thoroughly to determine whether these tu-
mors truly represented a distinct category of ovarian tumors
or not. The category of seromucinous carcinomas was espe-
cially problematic and some authors believed that these actu-
ally represented endometrioid carcinomas with mucinous
differentiation. They thus advocated its removal from the
classification. However, other authors believed that the
unique features of seromucinous carcinomas supported their
classification as distinct types of ovarian tumors. Finally, the
2020 5th Edition of WHO Classification of Female Genital
Tumors reversed Seromucinous carcinoma as a distinct en-
tity recategorizing them as endometrioid carcinoma with
mucinous differentiation. The 2020 WHO recognizes only
benign and borderline seromucinous tumors. A histogenesis
of seromucinous tumors from the secondary Mullerian sys-
tem or vestigial structures is favored.
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